Abivax (CHIX:ABVXP) Debt-to-Equity : 0.28 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Abivax Debt-to-Equity?

Abivax's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €10.61 Mil. Abivax's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €44.86 Mil. Abivax's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €196.01 Mil. Abivax's debt to equity for the quarter that ended in Dec. 2023 was 0.28.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Abivax's Debt-to-Equity or its related term are showing as below:

CHIX:ABVXp' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 1.12 Max: 5.45
Current: 0.28

During the past 11 years, the highest Debt-to-Equity Ratio of Abivax was 5.45. The lowest was 0.01. And the median was 1.12.

CHIX:ABVXp's Debt-to-Equity is ranked worse than
63.76% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs CHIX:ABVXp: 0.28

Abivax Debt-to-Equity Historical Data

The historical data trend for Abivax's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Debt-to-Equity Chart

Abivax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.12

1.90

1.73

5.45

0.28

Abivax Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.73	8.04	5.45	0.43	0.28

Competitive Comparison of Abivax's Debt-to-Equity

For the Biotechnology subindustry, Abivax's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abivax's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Abivax's Debt-to-Equity falls into.

Abivax Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Abivax's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.607	+	44.857)	/	196.01
	=	0.28

Abivax's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.607	+	44.857)	/	196.01
	=	0.28

Abivax (CHIX:ABVXp) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Abivax Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Abivax's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax (CHIX:ABVXP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (CHIX:ABVXp) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ABVX:USA AAVXF:USA ABVX:France 2X10:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based biotechnology company. It is focused on using antiviral technology platforms targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein in the nucleus or the cytoplasm of the infected cell during viral infection, the Immune stimulation platform focuses on invariant natural killer agonists and the Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma.

Abivax (CHIX:ABVXP) Headlines

No Headlines